IsoTis takes bone graft to US dental market:
This article was originally published in Clinica
IsoTis OrthoBiologics has received US FDA 510(k) clearance to use its advanced synthetic bone graft material, OsSatura BCP, in dental applications. The company, which already markets in the US demineralised bone matrix (DBM) product range, said that the dental field represented a strong area of growth for IsoTis. The dental arena accounts for around 10% of the Lausanne, Switzerland firm's sales. The new dental product is composed of approximately 80% hydroxyapatite and 20% ss-tricalcium phosphate.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.